Role of cytokines in rheumatoid arthritis: An education in pathophysiology and therapeutics

Immunological Reviews

Volumn 223, Issue 1, 2008, Pages 7-19

  Feldmann, Marc ^a   Maini, Sir Ravinder N ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anti TNF therapy; Biology of TNF; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; COMPLEMENTARY DNA; CYTOKINE; ETANERCEPT; HLA DR ANTIGEN; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL MODEL; ANIMAL TISSUE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; GOOD CLINICAL PRACTICE; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATION; LOW DRUG DOSE; LYMPHOMA; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELL ADHESION; CELL MOVEMENT; CLINICAL TRIALS AS TOPIC; CRICETINAE; CYTOKINES; DRUG SYNERGISM; HUMANS; MICE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47249153519     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2008.00626.x     Document Type: Review

References (81)

1. Oppenheim JJ, Feldmann M, eds. Cytokine Reference. London : Academic Press, 2001.
2. Feldmann M, Maini RN. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003 9 : 1245 1250.
3. Vilcek J, Feldmann M. Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci 2004 25 : 201 209.
4. Haddad JJ. Cytokines and related receptor-mediated signaling pathways. Biochem Biophys Res Commun 2002 297 : 700 713.
5. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994 91 : 1198 1205.
6. Taniguchi T, Ohno S, Fujii-Kuriyama Y, Muramatsu M. The nucleotide sequence of human fibroblast interferon cDNA. Gene 1980 10 : 11 15.
7. Pennica D, Hayflick JS, Bringman TS, Palladino MA, Goeddel DV. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA 1985 82 : 6060 6064.
8. Klareskog L, Forsum U, Scheynius A, Kabelitz D, Wigzell H. Evidence in support of a self perpetuating HLA-DR dependent delayed type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci USA 1982 72 : 3632 3636.
9. Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 1983 2 : 1115 1119.
10. Londei M, Bottazzo GF, Feldmann M. Human T cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells. Science 1985 228 : 85 89.
11. Buchan G, Barrett K, Fujita T, Taniguchi T, Maini R, Feldmann M. Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. Clin Exp Immunol 1988 71 : 295 301.
12. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996 14 : 397 440.
13. Alvaro-Garcia JM, Zvaifler NJ, Brown CB, Kaushansky L, Firestein GS. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and TNFα. J Immunol 1991 146 : 3365 3371.
14. Wood NC, Symons JA, Dickens E, Duff GW. In situ hybridization of IL-6 in rheumatoid arthritis. Clin Exp Immunol 1992 87 : 183 189.
15. Saxne T, Palladino MA Jr., Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor a but not tumor necrosis factor b in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988 31 : 1041 1045.
16. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin Exp Immunol 1988 73 : 449 455.
17. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989 2 : 244 247.
18. Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994 179 : 1517 1527.
19. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Nat Acad Sci USA 1992 89 : 9784 9788.
20. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992 89 : 7375 7379.
21. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992 77 : 510 514.
22. Keffer J, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991 10 : 4025 4031.
23. Elliott MJ, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993 36 : 1681 1690.
24. Elliott MJ, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 344 : 1105 1110.
25. Elliott MJ, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994 344 : 1125 1127.
26. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994 91 : 2762 2766.
27. Williams RO, Ghrayeb J, Feldmann M, Maini RN. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995 84 : 433 439.
28. Weinblatt ME, et al. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1994 37 : 1492 1498.
29. Maini RN, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 41 : 1552 1563.
30. Genovese MC, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004 50 : 1412 1419.
31. Weinblatt M, Combe B, Covucci A, Arnada R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006 54 : 2807 2816.
32. Schroder O, Blumenstein I, Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur J Gastroenterol Hepatol 2006 18 : 11 16.
33. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002 50 : 206 211.
34. Maini RN, et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999 354 : 1932 1939.
35. Lipsky PE, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000 343 : 1594 1602.
36. Maini RN, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004 50 : 1051 1065.
37. Klareskog L, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004 363 : 675 681.
38. Breedveld FC, et al. The PREMIER study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006 54 : 26 37.
39. Hochberg MC, Tracey JK, Hawkins-Holts M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003 62 (Suppl.) : ii13 ii16.
40. Sandborn WJ, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001 121 : 1088 1094.
41. Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res 2002 4 (Suppl.) : S22 S28.
42. Charles P, et al. Regulation of cytokines, cytokine inhibitors and acute phase proteins following anti-TNFα therapy in rheumatoid arthritis. J Immunol 1999 163 : 1521 1528.
43. Feldmann M, Maini RN. Anti-TNFα therapy or rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001 19 : 163 196.
44. Cope AP, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994 94 : 749 760.
45. Ehrenstein MR, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004 200 : 273 276.
46. Blackburn WDJ, Chatham WW. Laboratory findings in rheumatoid arthritis. In : Koopman WJ, ed. Arthritis and Allied Conditions: A Textbook of Rheumatology, Vol. 1, 13th edn. Baltimore : Williams & Wilkins, 1997 : 1089 1107.
47. Davis D, Charles PJ, Potter A, Feldmann M, Maini RN, Elliott MJ. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor a blockade. Br J Rheumatol 1997 36 : 950 956.
48. Jacobsson LT, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005 32 : 1213 1218.
49. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007 56 : 2905 2912.
50. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996 39 : 1082 1091.
51. Tak PP, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor a monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996 39 : 1077 1081.
52. Taylor PC, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor a blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000 43 : 38 47.
53. Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol 1997 36 : 643 650.
54. Catrina AI, et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 2006 54 : 76 81.
55. Ziolkowska M, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa b ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002 46 : 1744 1753.
56. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990 33 : 305 315.
57. Bresnihan B, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998 41 : 2196 2204.
58. Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007 46 : 1140 1147.
59. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF α, anti-IL-1 α/β, and IL-1Ra. Arthritis Rheum 1996 39 : 797 809.
60. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB. IL-1 α β blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol 1999 163 : 5049 5055.
61. Nishimoto N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004 50 : 1761 1769.
62. Maini RN, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006 54 : 2817 2829.
63. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997 3 : 189 195.
64. Baslund B, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 2005 52 : 2686 2692.
65. McClung MR, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006 354 : 821 831.
66. van Dullemen HM, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995 109 : 129 135.
67. Targan SR, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997 337 : 1029 1035.
68. Ruperto N, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007 56 : 3096 3106.
69. Braun J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002 359 : 1187 1193.
70. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001 357 : 1842 1847.
71. van der Heijde D, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007 56 : 2698 2707.
72. Rutgeerts P, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353 : 2462 2476.
73. Quinn MA, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005 52 : 27 35.
74. Goekoop-Ruiteman YP, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis. (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005 11 : 3381 3390.
75. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 295 : 2275 2285.
76. Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatoid disease. Ann Rheum Dis 2007 66 (Suppl.) : iii2 iii22.
77. Baecklund E, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006 54 : 692 701.
78. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007 56 : 1433 1439.
79. Londei M, Lamb JR, Bottazzo GF, Feldmann M. Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature 1984 312 : 639 641.
80. Pujol-Borrell R, et al. HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature 1987 326 : 304 306.
81. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996 85 : 307 310.